Genetic Profile of Gliosarcomas

2000/02/01 by Rui M. Reis, Rui Manuel Reis, Dilek Könü-Lebleblicioglu +4 · 26 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Glioma Diagnosis and Treatment #Protein Degradation and Inhibitors #Chromatin Remodeling and Cancer

paper · pdf · doi:10.1016/s0002-9440(10)64746-3

Cited by

• Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants
• Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. [europepmc]
• Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. [europepmc]
• Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. [europepmc]
• Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. [europepmc]
• Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. [europepmc]
• Transcriptional factors for epithelial-mesenchymal transition are associated with mesenchymal differentiation in gliosarcoma. [europepmc]
• Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro. [europepmc]
• Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. [europepmc]
• C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. [europepmc]
• Targeting Aggressive Cancer Stem Cells in Glioblastoma. [europepmc]
• Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. [europepmc]
• Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. [europepmc]
• Chemotherapy for intracranial ependymoma in adults. [europepmc]
• AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors. [europepmc]
• Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. [europepmc]
• Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma. [europepmc]
• Gliosarcoma Is Driven by Alterations in PI3K/Akt, RAS/MAPK Pathways and Characterized by Collagen Gene Expression Signature. [europepmc]
• Gliosarcoma: distinct molecular pathways and genomic alterations identified by DNA copy number/SNP microarray analysis. [europepmc]
• LKB1 deficiency promotes proliferation and invasion of glioblastoma through activation of mTOR and focal adhesion kinase signaling pathways. [europepmc]
• Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma. [europepmc]
• Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma. [europepmc]
• IDH1-mutant primary intraventricular gliosarcoma: Case report and systematic review of a rare location and molecular profile. [europepmc]
• TERT Promoter Alterations in Glioblastoma: A Systematic Review. [europepmc]
• Genomic landscape of gliosarcoma: distinguishing features and targetable alterations. [europepmc]
• Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. [europepmc]